Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial GuidancePRNewsWire • 02/28/24
Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPSZacks Investment Research • 02/23/24
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024PRNewsWire • 02/14/24
Redx Pharma inks $880m deal with Jazz Pharma; will bank $10m immediatelyProactive Investors • 02/07/24
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor ProgramPRNewsWire • 02/07/24
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024InvestorPlace • 01/31/24
Jazz Pharmaceuticals targets positive momentum in 2024, receives Outperform ratingProactive Investors • 01/03/24
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress DisorderPRNewsWire • 12/21/23
Jazz Pharmaceuticals' Zanidatamab Promises Growth Amidst Market UndervaluationSeeking Alpha • 12/21/23
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 12/20/23